Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results

By C. Qi, J. Gong, Jian Li, Dan Liu, Yanru Qin, S. Ge, Miao Zhang, Zhi Peng, Jun Zhou, Yanshuo Cao and 16 more. 2022

Subfields: Immunology, Oncology

Citations in the corpus

• Immunohistochemical Analysis of Potential Therapeutic Targets PRAME, FOLR1, and CLDN18.2 in Salivary Gland Carcinomas (2026, unknown): “2 positivity (3/54 tumors) precludes meaningful clinical interpretation, despite its role in gastrointestinal cancer therapeutics [32, 33].”